The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications skewing public discussions about the cost of pharmaceutical research and ...

The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications skewing public discussions about the cost of pharmaceutical research and ...

The recent announcement that the National Institutes of Health would cap reimbursement of facilities and administrative (F&A) costs on research grants at 15% would significantly slow or cease ...

F&A [Facilities & Administrative] costs, also known as IER [Indirect Expense Recovery] or Indirect Costs, are real costs that are necessary to cover expenses which cannot be charged directly to a ...

Aliasger K. Salem receives funding from the National Institutes of Health. He serves on the Executive Board of the American Association for Pharmaceutical Scientists. Biomedical research in the U.S.

Two months after the National Institutes of Health unilaterally capped indirect research cost reimbursement rates at 15 percent—which a federal judge has permanently blocked—the Department of Energy ...